$-0.08
(Market cap
$525 Mln
Recently Viewed
Clear AllMarket cap
$525 Mln
Revenue (TTM)
$403 Mln
P/E Ratio
--
P/B Ratio
98.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-2.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
9.5
Debt to Equity
-1.8
Book Value
$--
EPS
$-0.1
Face value
--
Shares outstanding
257,404,876
CFO
$-1,127.49 Mln
EBITDA
$-1,296.01 Mln
Net Profit
$-1,621.04 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Esperion Therapeutics (ESPR)
| -50.4 | -30.0 | -41.6 | 93.3 | 12.8 | -41.8 | -21.0 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Esperion Therapeutics (ESPR)
| 68.2 | -26.2 | -52.0 | 24.6 | -80.8 | -56.4 | 29.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Esperion Therapeutics (ESPR)
|
1.8 | 525.1 | 403.1 | -22.7 | 15.5 | 6.6 | -- | 98.4 |
| 12.5 | 4,437.3 | 3,018.8 | 72.1 | 12.6 | -80 | 63.2 | 105.4 | |
| 40.9 | 5,228.7 | 1,003.8 | 22.4 | 6.8 | 7.5 | 227.2 | 14.1 | |
| 184.4 | 9,667.5 | 638.5 | -183.2 | -27.4 | -252.1 | -- | 109.5 | |
| 74.7 | 14,879.0 | 502.1 | -729.3 | -125.8 | 41.2 | -- | 123.7 | |
| 45.2 | 4,910.2 | 761.4 | 99.7 | 7.3 | 15 | 56.3 | 7.6 | |
| 13.6 | 10,903.7 | 345,831.0 | 56,586.0 | 21.5 | 15.8 | 17.9 | 2.7 | |
| 22.2 | 11,550.7 | 4,715.0 | -232.0 | 0.9 | -3.7 | -- | 1.8 | |
| 8.1 | 7,186.6 | 7,227.1 | 386.1 | 16.6 | 6.9 | 13.5 | 1.0 | |
| 226.9 | 4,622.8 | 268.1 | 124.5 | 60.0 | 13.5 | 37.8 | 4.4 |
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include... NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan. Read more
President, CEO & Director
Mr. Sheldon L. Koenig
President, CEO & Director
Mr. Sheldon L. Koenig
Headquarters
Ann Arbor, MI
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Esperion Therapeutics Inc (ESPR) is $1.84 (NASDAQ) as of 24-Apr-2026 10:40 EDT. Esperion Therapeutics Inc (ESPR) has given a return of 12.76% in the last 3 years.
Since, TTM earnings of Esperion Therapeutics Inc (ESPR) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-46.42
|
-3.49
|
|
2024
|
-8.31
|
-1.11
|
|
2023
|
-1.61
|
-0.74
|
|
2022
|
-1.96
|
-1.41
|
|
2021
|
-0.68
|
-0.94
|
The 52-week high and low of Esperion Therapeutics Inc (ESPR) are Rs 4.18 and Rs 0.69 as of 24-Apr-2026.
Esperion Therapeutics Inc (ESPR) has a market capitalisation of $ 525 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Esperion Therapeutics Inc (ESPR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.